Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Cash from Operations (2017 - 2025)

Historic Cash from Operations for Aclaris Therapeutics (ACRS) over the last 9 years, with Q3 2025 value amounting to -$10.9 million.

  • Aclaris Therapeutics' Cash from Operations fell 14969.09% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$42.9 million, marking a year-over-year decrease of 13980.33%. This contributed to the annual value of -$20.1 million for FY2024, which is 7436.96% up from last year.
  • Latest data reveals that Aclaris Therapeutics reported Cash from Operations of -$10.9 million as of Q3 2025, which was down 14969.09% from -$10.0 million recorded in Q2 2025.
  • Aclaris Therapeutics' Cash from Operations' 5-year high stood at $22.0 million during Q3 2024, with a 5-year trough of -$26.4 million in Q1 2023.
  • Moreover, its 5-year median value for Cash from Operations was -$12.3 million (2024), whereas its average is -$13.3 million.
  • In the last 5 years, Aclaris Therapeutics' Cash from Operations tumbled by 21414.87% in 2023 and then surged by 18958.75% in 2024.
  • Over the past 5 years, Aclaris Therapeutics' Cash from Operations (Quarter) stood at -$17.1 million in 2021, then dropped by 11.95% to -$19.1 million in 2022, then surged by 64.63% to -$6.8 million in 2023, then crashed by 32.2% to -$8.9 million in 2024, then fell by 22.31% to -$10.9 million in 2025.
  • Its last three reported values are -$10.9 million in Q3 2025, -$10.0 million for Q2 2025, and -$13.1 million during Q1 2025.